The validation of surrogate end points by using data from randomized clinical trials: a case‐study in advanced colorectal cancer

Tomasz Burzykowski, Geert Molenberghs and Marc Buyse

Journal of the Royal Statistical Society Series A, 2004, vol. 167, issue 1, 103-124

Abstract: Summary. In many therapeutic areas, the identification and validation of surrogate end points is of prime interest to reduce the duration and/or size of clinical trials. Buyse and co‐workers and Burzykowski and co‐workers have proposed a validation strategy for end points that are either normally distributed or (possibly censored) failure times. In this paper, we address the problem of validating an ordinal categorical or binary end point as a surrogate for a failure time true end point. In particular, we investigate the validity of tumour response as a surrogate for survival time in evaluating fluoropyrimidine‐based experimental therapies for advanced colorectal cancer. Our analysis is performed on data from 28 randomized trials in advanced colorectal cancer, which are available through the Meta‐Analysis Group in Cancer.

Date: 2004
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (6)

Downloads: (external link)
https://doi.org/10.1111/j.1467-985X.2004.00293.x

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:bla:jorssa:v:167:y:2004:i:1:p:103-124

Ordering information: This journal article can be ordered from
http://ordering.onli ... 1111/(ISSN)1467-985X

Access Statistics for this article

Journal of the Royal Statistical Society Series A is currently edited by A. Chevalier and L. Sharples

More articles in Journal of the Royal Statistical Society Series A from Royal Statistical Society Contact information at EDIRC.
Bibliographic data for series maintained by Wiley Content Delivery ().